Precision Therapies Will Serve Aging Populations While Facing Regulatory Delays
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
13 Jul 25
Updated
15 Aug 25
AnalystHighTarget's Fair Value
US$57.00
34.3% undervalued intrinsic discount15 Aug
US$37.45
1Y
-17.6%7D
6.8%